The cytokine TNF-α is a major drug target for rheumatoid arthritis, an
inflammatory joint disorder. An alternative approach is to target the protease
TNF-α convertase (TACE), which releases TNF-α from cells.
However, because TACE cleaves other proteins involved in development and cancer, a
tissue-specific inhibition of TACE in immune cells appears mandatory. In this issue
of the
Stefan F. Lichtenthaler
The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.